nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Dactinomycin—muscle cancer	0.11	0.15	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—muscle cancer	0.0883	0.121	CbGbCtD
Dabrafenib—ABCG2—Vincristine—muscle cancer	0.0675	0.0927	CbGbCtD
Dabrafenib—ABCG2—Etoposide—muscle cancer	0.0618	0.0849	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—muscle cancer	0.0514	0.0706	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—muscle cancer	0.0475	0.0652	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—muscle cancer	0.0422	0.0579	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—muscle cancer	0.0409	0.0561	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—muscle cancer	0.0395	0.0543	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—muscle cancer	0.0331	0.0454	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—muscle cancer	0.0329	0.0452	CbGbCtD
Dabrafenib—ABCB1—Vincristine—muscle cancer	0.0243	0.0334	CbGbCtD
Dabrafenib—ABCB1—Etoposide—muscle cancer	0.0223	0.0306	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—muscle cancer	0.0152	0.0209	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—muscle cancer	0.0147	0.0202	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—muscle cancer	0.0146	0.02	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—muscle cancer	0.0134	0.0183	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—muscle cancer	0.00911	0.0125	CbGbCtD
Dabrafenib—NEK11—testis—muscle cancer	0.00397	0.0697	CbGeAlD
Dabrafenib—LIMK1—tendon—muscle cancer	0.00344	0.0603	CbGeAlD
Dabrafenib—LIMK1—vagina—muscle cancer	0.00319	0.0559	CbGeAlD
Dabrafenib—LIMK1—testis—muscle cancer	0.00284	0.0499	CbGeAlD
Dabrafenib—RAF1—embryo—muscle cancer	0.00239	0.042	CbGeAlD
Dabrafenib—SIK1—renal system—muscle cancer	0.00228	0.0399	CbGeAlD
Dabrafenib—BRAF—tendon—muscle cancer	0.00212	0.0372	CbGeAlD
Dabrafenib—BRAF—bone marrow—muscle cancer	0.00206	0.0361	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—muscle cancer	0.00204	0.0358	CbGeAlD
Dabrafenib—BRAF—vagina—muscle cancer	0.00197	0.0346	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—muscle cancer	0.00188	0.033	CbGeAlD
Dabrafenib—RAF1—renal system—muscle cancer	0.00181	0.0318	CbGeAlD
Dabrafenib—SIK1—tendon—muscle cancer	0.00178	0.0312	CbGeAlD
Dabrafenib—BRAF—testis—muscle cancer	0.00176	0.0308	CbGeAlD
Dabrafenib—SIK1—bone marrow—muscle cancer	0.00172	0.0302	CbGeAlD
Dabrafenib—SLCO1B3—vagina—muscle cancer	0.0017	0.0298	CbGeAlD
Dabrafenib—RAF1—cardiac atrium—muscle cancer	0.00162	0.0285	CbGeAlD
Dabrafenib—SIK1—head—muscle cancer	0.00152	0.0267	CbGeAlD
Dabrafenib—SIK1—testis—muscle cancer	0.00147	0.0258	CbGeAlD
Dabrafenib—RAF1—tendon—muscle cancer	0.00141	0.0248	CbGeAlD
Dabrafenib—RAF1—bone marrow—muscle cancer	0.00137	0.024	CbGeAlD
Dabrafenib—SLCO1B1—renal system—muscle cancer	0.00136	0.0238	CbGeAlD
Dabrafenib—RAF1—vagina—muscle cancer	0.00131	0.023	CbGeAlD
Dabrafenib—RAF1—head—muscle cancer	0.00121	0.0213	CbGeAlD
Dabrafenib—RAF1—testis—muscle cancer	0.00117	0.0205	CbGeAlD
Dabrafenib—SLC22A8—renal system—muscle cancer	0.00105	0.0185	CbGeAlD
Dabrafenib—CYP2C8—renal system—muscle cancer	0.000771	0.0135	CbGeAlD
Dabrafenib—SLC22A8—head—muscle cancer	0.000705	0.0124	CbGeAlD
Dabrafenib—Rash erythematous—Doxorubicin—muscle cancer	0.000628	0.00488	CcSEcCtD
Dabrafenib—Stomatitis—Vincristine—muscle cancer	0.000624	0.00485	CcSEcCtD
Dabrafenib—Bone disorder—Methotrexate—muscle cancer	0.000615	0.00478	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.000611	0.00475	CcSEcCtD
Dabrafenib—Rash pustular—Doxorubicin—muscle cancer	0.000603	0.00469	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000594	0.00462	CcSEcCtD
Dabrafenib—Rigors—Doxorubicin—muscle cancer	0.000589	0.00458	CcSEcCtD
Dabrafenib—Chills—Dactinomycin—muscle cancer	0.000577	0.00449	CcSEcCtD
Dabrafenib—Alopecia—Dactinomycin—muscle cancer	0.000569	0.00442	CcSEcCtD
Dabrafenib—Urinary tract disorder—Vincristine—muscle cancer	0.000568	0.00441	CcSEcCtD
Dabrafenib—ABCG2—bone marrow—muscle cancer	0.000567	0.00994	CbGeAlD
Dabrafenib—Connective tissue disorder—Vincristine—muscle cancer	0.000565	0.00439	CcSEcCtD
Dabrafenib—Urethral disorder—Vincristine—muscle cancer	0.000564	0.00438	CcSEcCtD
Dabrafenib—Neoplasm malignant—Doxorubicin—muscle cancer	0.000563	0.00438	CcSEcCtD
Dabrafenib—Erythema—Dactinomycin—muscle cancer	0.00056	0.00435	CcSEcCtD
Dabrafenib—CYP2C8—vagina—muscle cancer	0.000558	0.00979	CbGeAlD
Dabrafenib—Neutropenia—Etoposide—muscle cancer	0.000544	0.00423	CcSEcCtD
Dabrafenib—ABCG2—vagina—muscle cancer	0.000543	0.00952	CbGeAlD
Dabrafenib—Bone disorder—Doxorubicin—muscle cancer	0.000533	0.00414	CcSEcCtD
Dabrafenib—Cellulitis—Doxorubicin—muscle cancer	0.000529	0.00411	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000529	0.00411	CcSEcCtD
Dabrafenib—Hypocalcaemia—Doxorubicin—muscle cancer	0.000525	0.00408	CcSEcCtD
Dabrafenib—CYP3A4—renal system—muscle cancer	0.000522	0.00916	CbGeAlD
Dabrafenib—Angiopathy—Vincristine—muscle cancer	0.000522	0.00405	CcSEcCtD
Dabrafenib—Infestation NOS—Etoposide—muscle cancer	0.000519	0.00403	CcSEcCtD
Dabrafenib—Infestation—Etoposide—muscle cancer	0.000519	0.00403	CcSEcCtD
Dabrafenib—Mediastinal disorder—Vincristine—muscle cancer	0.000518	0.00403	CcSEcCtD
Dabrafenib—Anaemia—Dactinomycin—muscle cancer	0.000518	0.00402	CcSEcCtD
Dabrafenib—Renal failure—Etoposide—muscle cancer	0.00051	0.00396	CcSEcCtD
Dabrafenib—Alopecia—Vincristine—muscle cancer	0.000508	0.00395	CcSEcCtD
Dabrafenib—Stomatitis—Etoposide—muscle cancer	0.000506	0.00393	CcSEcCtD
Dabrafenib—Creatinine increased—Doxorubicin—muscle cancer	0.000505	0.00393	CcSEcCtD
Dabrafenib—Mental disorder—Vincristine—muscle cancer	0.000504	0.00392	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—muscle cancer	0.000502	0.0039	CcSEcCtD
Dabrafenib—Leukopenia—Dactinomycin—muscle cancer	0.000501	0.0039	CcSEcCtD
Dabrafenib—CYP2C8—testis—muscle cancer	0.000498	0.00874	CbGeAlD
Dabrafenib—ABCB1—embryo—muscle cancer	0.000488	0.00857	CbGeAlD
Dabrafenib—ABCG2—testis—muscle cancer	0.000484	0.0085	CbGeAlD
Dabrafenib—Back pain—Vincristine—muscle cancer	0.000484	0.00376	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.000481	0.00374	CcSEcCtD
Dabrafenib—Myalgia—Dactinomycin—muscle cancer	0.000477	0.00371	CcSEcCtD
Dabrafenib—Hyperkalaemia—Doxorubicin—muscle cancer	0.000473	0.00367	CcSEcCtD
Dabrafenib—Influenza like illness—Doxorubicin—muscle cancer	0.000467	0.00363	CcSEcCtD
Dabrafenib—Anaemia—Vincristine—muscle cancer	0.000463	0.0036	CcSEcCtD
Dabrafenib—Urinary tract disorder—Etoposide—muscle cancer	0.00046	0.00357	CcSEcCtD
Dabrafenib—Oedema—Dactinomycin—muscle cancer	0.000457	0.00355	CcSEcCtD
Dabrafenib—Urethral disorder—Etoposide—muscle cancer	0.000457	0.00355	CcSEcCtD
Dabrafenib—Infection—Dactinomycin—muscle cancer	0.000454	0.00353	CcSEcCtD
Dabrafenib—Leukopenia—Vincristine—muscle cancer	0.000448	0.00348	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000448	0.00348	CcSEcCtD
Dabrafenib—Rash maculo-papular—Doxorubicin—muscle cancer	0.000437	0.0034	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—muscle cancer	0.000437	0.00339	CcSEcCtD
Dabrafenib—Eye disorder—Etoposide—muscle cancer	0.000435	0.00338	CcSEcCtD
Dabrafenib—Neoplasm—Doxorubicin—muscle cancer	0.000435	0.00338	CcSEcCtD
Dabrafenib—Hypertension—Vincristine—muscle cancer	0.000432	0.00336	CcSEcCtD
Dabrafenib—Myalgia—Vincristine—muscle cancer	0.000426	0.00331	CcSEcCtD
Dabrafenib—Angiopathy—Etoposide—muscle cancer	0.000423	0.00328	CcSEcCtD
Dabrafenib—Immune system disorder—Etoposide—muscle cancer	0.000421	0.00327	CcSEcCtD
Dabrafenib—Mediastinal disorder—Etoposide—muscle cancer	0.00042	0.00326	CcSEcCtD
Dabrafenib—Chills—Etoposide—muscle cancer	0.000418	0.00325	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000417	0.00324	CcSEcCtD
Dabrafenib—Alopecia—Etoposide—muscle cancer	0.000412	0.0032	CcSEcCtD
Dabrafenib—Oedema—Vincristine—muscle cancer	0.000408	0.00317	CcSEcCtD
Dabrafenib—Infection—Vincristine—muscle cancer	0.000406	0.00315	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000401	0.00312	CcSEcCtD
Dabrafenib—Nervous system disorder—Vincristine—muscle cancer	0.000401	0.00311	CcSEcCtD
Dabrafenib—Thrombocytopenia—Vincristine—muscle cancer	0.0004	0.00311	CcSEcCtD
Dabrafenib—Decreased appetite—Dactinomycin—muscle cancer	0.000397	0.00309	CcSEcCtD
Dabrafenib—Hyperhidrosis—Vincristine—muscle cancer	0.000395	0.00307	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—muscle cancer	0.000394	0.00306	CcSEcCtD
Dabrafenib—Back pain—Etoposide—muscle cancer	0.000392	0.00305	CcSEcCtD
Dabrafenib—Muscle spasms—Etoposide—muscle cancer	0.00039	0.00303	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000385	0.00299	CcSEcCtD
Dabrafenib—Hypotension—Vincristine—muscle cancer	0.000382	0.00297	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—muscle cancer	0.000378	0.00294	CcSEcCtD
Dabrafenib—Anaemia—Etoposide—muscle cancer	0.000375	0.00291	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000374	0.00291	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000372	0.00289	CcSEcCtD
Dabrafenib—ABCB1—renal system—muscle cancer	0.00037	0.00648	CbGeAlD
Dabrafenib—Insomnia—Vincristine—muscle cancer	0.000369	0.00287	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—muscle cancer	0.000365	0.00284	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—muscle cancer	0.000363	0.00282	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—muscle cancer	0.000361	0.00281	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—muscle cancer	0.000361	0.00281	CcSEcCtD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—FOXO1—muscle cancer	0.000356	0.00414	CbGpPWpGaD
Dabrafenib—Decreased appetite—Vincristine—muscle cancer	0.000355	0.00276	CcSEcCtD
Dabrafenib—Cough—Etoposide—muscle cancer	0.000354	0.00275	CcSEcCtD
Dabrafenib—RAF1—Kit receptor signaling pathway—KIT—muscle cancer	0.000353	0.0041	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IGF2—muscle cancer	0.000353	0.0041	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000353	0.00274	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—muscle cancer	0.000352	0.00274	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—muscle cancer	0.000351	0.00272	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—muscle cancer	0.00035	0.00272	CcSEcCtD
Dabrafenib—Constipation—Vincristine—muscle cancer	0.000349	0.00271	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—muscle cancer	0.000349	0.00271	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000343	0.00266	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—muscle cancer	0.000342	0.00266	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—muscle cancer	0.000337	0.00262	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000336	0.0039	CbGpPWpGaD
Dabrafenib—Abdominal discomfort—Methotrexate—muscle cancer	0.000334	0.0026	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—muscle cancer	0.000334	0.0026	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000334	0.00388	CbGpPWpGaD
Dabrafenib—Infection—Etoposide—muscle cancer	0.000329	0.00256	CcSEcCtD
Dabrafenib—RAF1—VEGFR2 mediated cell proliferation—VEGFA—muscle cancer	0.000329	0.00381	CbGpPWpGaD
Dabrafenib—Asthenia—Dactinomycin—muscle cancer	0.000328	0.00255	CcSEcCtD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000327	0.0038	CbGpPWpGaD
Dabrafenib—Blood creatinine increased—Doxorubicin—muscle cancer	0.000327	0.00254	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—muscle cancer	0.000326	0.00253	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—muscle cancer	0.000325	0.00252	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—muscle cancer	0.000324	0.00252	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—muscle cancer	0.000323	0.00251	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—muscle cancer	0.000323	0.00251	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—muscle cancer	0.000321	0.0025	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—muscle cancer	0.00032	0.00249	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—muscle cancer	0.00032	0.00249	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—muscle cancer	0.000319	0.00248	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.000319	0.0037	CbGpPWpGaD
Dabrafenib—Hypokalaemia—Doxorubicin—muscle cancer	0.000318	0.00247	CcSEcCtD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000316	0.00367	CbGpPWpGaD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000314	0.00244	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000313	0.00363	CbGpPWpGaD
Dabrafenib—Diarrhoea—Dactinomycin—muscle cancer	0.000313	0.00243	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—muscle cancer	0.000312	0.00243	CcSEcCtD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.000312	0.00362	CbGpPWpGaD
Dabrafenib—Infestation NOS—Methotrexate—muscle cancer	0.000311	0.00242	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—muscle cancer	0.000311	0.00242	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.000309	0.00359	CbGpPWpGaD
Dabrafenib—Hypotension—Etoposide—muscle cancer	0.000309	0.0024	CcSEcCtD
Dabrafenib—SIK1—Circadian rythm related genes—TP53—muscle cancer	0.000308	0.00358	CbGpPWpGaD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000308	0.00239	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—muscle cancer	0.000305	0.00237	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—muscle cancer	0.000303	0.00235	CcSEcCtD
Dabrafenib—RAF1—BDNF signaling pathway—CNR1—muscle cancer	0.000302	0.00351	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Vincristine—muscle cancer	0.000301	0.00234	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000299	0.00348	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000299	0.00347	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—FOXO1—muscle cancer	0.000299	0.00347	CbGpPWpGaD
Dabrafenib—Haematuria—Methotrexate—muscle cancer	0.000296	0.0023	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—muscle cancer	0.000296	0.0023	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—FOXO4—muscle cancer	0.000295	0.00342	CbGpPWpGaD
Dabrafenib—Epistaxis—Methotrexate—muscle cancer	0.000293	0.00228	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—muscle cancer	0.000293	0.00228	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—FOXO4—muscle cancer	0.000293	0.0034	CbGpPWpGaD
Dabrafenib—Vomiting—Dactinomycin—muscle cancer	0.000291	0.00226	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—muscle cancer	0.000288	0.00224	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—muscle cancer	0.000288	0.00224	CcSEcCtD
Dabrafenib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.000287	0.00333	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000286	0.00222	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—muscle cancer	0.000285	0.00222	CcSEcCtD
Dabrafenib—Constipation—Etoposide—muscle cancer	0.000283	0.0022	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—muscle cancer	0.000282	0.00219	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—FOXO4—muscle cancer	0.000281	0.00327	CbGpPWpGaD
Dabrafenib—Haemoglobin—Methotrexate—muscle cancer	0.00028	0.00218	CcSEcCtD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.00028	0.00325	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FOXO4—muscle cancer	0.00028	0.00325	CbGpPWpGaD
Dabrafenib—Diarrhoea—Vincristine—muscle cancer	0.000279	0.00217	CcSEcCtD
Dabrafenib—ABCB1—bone marrow—muscle cancer	0.000279	0.0049	CbGeAlD
Dabrafenib—Haemorrhage—Methotrexate—muscle cancer	0.000279	0.00217	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB2—FOXO4—muscle cancer	0.000279	0.00323	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000278	0.00323	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FOXO4—muscle cancer	0.000277	0.00322	CbGpPWpGaD
Dabrafenib—Urinary tract disorder—Methotrexate—muscle cancer	0.000276	0.00214	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—muscle cancer	0.000273	0.00213	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—MYOG—muscle cancer	0.000273	0.00317	CbGpPWpGaD
Dabrafenib—BRAF—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.000273	0.00317	CbGpPWpGaD
Dabrafenib—Hyperglycaemia—Doxorubicin—muscle cancer	0.000272	0.00212	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—muscle cancer	0.000272	0.00211	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—muscle cancer	0.000271	0.0021	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—muscle cancer	0.00027	0.0021	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—muscle cancer	0.000269	0.00209	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—muscle cancer	0.000269	0.00209	CcSEcCtD
Dabrafenib—ABCB1—vagina—muscle cancer	0.000268	0.0047	CbGeAlD
Dabrafenib—Renal failure—Doxorubicin—muscle cancer	0.000265	0.00206	CcSEcCtD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000262	0.00305	CbGpPWpGaD
Dabrafenib—Stomatitis—Doxorubicin—muscle cancer	0.000262	0.00204	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000262	0.00304	CbGpPWpGaD
Dabrafenib—Body temperature increased—Etoposide—muscle cancer	0.000262	0.00203	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—muscle cancer	0.000262	0.00203	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—muscle cancer	0.000262	0.00203	CcSEcCtD
Dabrafenib—RAF1—DAP12 interactions—FOXO4—muscle cancer	0.000261	0.00303	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000261	0.00303	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000261	0.00303	CbGpPWpGaD
Dabrafenib—Eye disorder—Methotrexate—muscle cancer	0.000261	0.00203	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—muscle cancer	0.00026	0.00202	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—FOXO4—muscle cancer	0.000258	0.003	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000258	0.00299	CbGpPWpGaD
Dabrafenib—Rash—Vincristine—muscle cancer	0.000258	0.002	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—muscle cancer	0.000257	0.002	CcSEcCtD
Dabrafenib—BRAF—Signaling by NGF—FOXO4—muscle cancer	0.000257	0.00298	CbGpPWpGaD
Dabrafenib—Haematuria—Doxorubicin—muscle cancer	0.000257	0.00199	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.000256	0.00297	CbGpPWpGaD
Dabrafenib—Headache—Vincristine—muscle cancer	0.000256	0.00199	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—FOXO4—muscle cancer	0.000255	0.00296	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.000254	0.00295	CbGpPWpGaD
Dabrafenib—Epistaxis—Doxorubicin—muscle cancer	0.000254	0.00197	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000254	0.00295	CbGpPWpGaD
Dabrafenib—Angiopathy—Methotrexate—muscle cancer	0.000253	0.00197	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—muscle cancer	0.000252	0.00196	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—muscle cancer	0.000251	0.00195	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CD34—muscle cancer	0.000251	0.00291	CbGpPWpGaD
Dabrafenib—Chills—Methotrexate—muscle cancer	0.00025	0.00195	CcSEcCtD
Dabrafenib—ABCB1—head—muscle cancer	0.000247	0.00434	CbGeAlD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000247	0.00286	CbGpPWpGaD
Dabrafenib—Alopecia—Methotrexate—muscle cancer	0.000247	0.00192	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000245	0.00285	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—FOXO1—muscle cancer	0.000245	0.00284	CbGpPWpGaD
Dabrafenib—Mental disorder—Methotrexate—muscle cancer	0.000244	0.0019	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—muscle cancer	0.000244	0.00189	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—muscle cancer	0.000243	0.00189	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—muscle cancer	0.000243	0.00189	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—muscle cancer	0.000243	0.00189	CcSEcCtD
Dabrafenib—Nausea—Vincristine—muscle cancer	0.000243	0.00189	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—muscle cancer	0.000242	0.00188	CcSEcCtD
Dabrafenib—ABCB1—testis—muscle cancer	0.000239	0.00419	CbGeAlD
Dabrafenib—Urinary tract disorder—Doxorubicin—muscle cancer	0.000239	0.00185	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—muscle cancer	0.000238	0.00185	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—muscle cancer	0.000237	0.00185	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—muscle cancer	0.000237	0.00185	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—muscle cancer	0.000237	0.00184	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—muscle cancer	0.000235	0.00183	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—muscle cancer	0.000234	0.00182	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—FOXO1—muscle cancer	0.000231	0.00268	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000231	0.00268	CbGpPWpGaD
Dabrafenib—Vision blurred—Methotrexate—muscle cancer	0.000229	0.00178	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR—KIT—muscle cancer	0.000228	0.00264	CbGpPWpGaD
Dabrafenib—Diarrhoea—Etoposide—muscle cancer	0.000226	0.00176	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—muscle cancer	0.000226	0.00175	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—muscle cancer	0.000224	0.00174	CcSEcCtD
Dabrafenib—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000222	0.00257	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000221	0.00257	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.000221	0.00256	CbGpPWpGaD
Dabrafenib—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00022	0.00255	CbGpPWpGaD
Dabrafenib—Angiopathy—Doxorubicin—muscle cancer	0.000219	0.0017	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—muscle cancer	0.000219	0.0017	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—muscle cancer	0.000218	0.0017	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000218	0.00169	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—FOXO1—muscle cancer	0.000218	0.00253	CbGpPWpGaD
Dabrafenib—Leukopenia—Methotrexate—muscle cancer	0.000217	0.00169	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—muscle cancer	0.000217	0.00168	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—FOXO1—muscle cancer	0.000216	0.00251	CbGpPWpGaD
Dabrafenib—Arrhythmia—Doxorubicin—muscle cancer	0.000216	0.00168	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—VEGFA—muscle cancer	0.000214	0.00249	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.000214	0.00248	CbGpPWpGaD
Dabrafenib—Alopecia—Doxorubicin—muscle cancer	0.000213	0.00166	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR in disease—KIT—muscle cancer	0.000212	0.00246	CbGpPWpGaD
Dabrafenib—Cough—Methotrexate—muscle cancer	0.000212	0.00165	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—muscle cancer	0.000212	0.00164	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—muscle cancer	0.00021	0.00164	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—muscle cancer	0.00021	0.00163	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—muscle cancer	0.00021	0.00163	CcSEcCtD
Dabrafenib—RAF1—Insulin Signaling—FOXO1—muscle cancer	0.000209	0.00242	CbGpPWpGaD
Dabrafenib—Rash—Etoposide—muscle cancer	0.000209	0.00162	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—muscle cancer	0.000208	0.00162	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—FOXO1—muscle cancer	0.000208	0.00241	CbGpPWpGaD
Dabrafenib—Headache—Etoposide—muscle cancer	0.000207	0.00161	CcSEcCtD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000207	0.0024	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FOXO1—muscle cancer	0.000207	0.0024	CbGpPWpGaD
Dabrafenib—Myalgia—Methotrexate—muscle cancer	0.000207	0.00161	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—muscle cancer	0.000207	0.00161	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB2—FOXO1—muscle cancer	0.000206	0.00239	CbGpPWpGaD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000205	0.0016	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—FOXO1—muscle cancer	0.000205	0.00238	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000204	0.00237	CbGpPWpGaD
Dabrafenib—Back pain—Doxorubicin—muscle cancer	0.000203	0.00158	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—muscle cancer	0.000202	0.00157	CcSEcCtD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000202	0.00234	CbGpPWpGaD
Dabrafenib—Vision blurred—Doxorubicin—muscle cancer	0.000198	0.00154	CcSEcCtD
Dabrafenib—Infection—Methotrexate—muscle cancer	0.000197	0.00153	CcSEcCtD
Dabrafenib—Nausea—Etoposide—muscle cancer	0.000197	0.00153	CcSEcCtD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000196	0.00227	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Methotrexate—muscle cancer	0.000194	0.00151	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—muscle cancer	0.000194	0.00151	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—muscle cancer	0.000194	0.00151	CcSEcCtD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000193	0.00225	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000193	0.00224	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FOXO1—muscle cancer	0.000193	0.00224	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000193	0.00224	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000193	0.00224	CbGpPWpGaD
Dabrafenib—Skin disorder—Methotrexate—muscle cancer	0.000193	0.0015	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—muscle cancer	0.000192	0.00149	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—FOXO1—muscle cancer	0.000191	0.00222	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00019	0.0022	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FOXO1—muscle cancer	0.00019	0.0022	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.000189	0.0022	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	0.000189	0.00219	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FOXO1—muscle cancer	0.000188	0.00219	CbGpPWpGaD
Dabrafenib—Leukopenia—Doxorubicin—muscle cancer	0.000188	0.00146	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000188	0.00218	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ANGPT2—muscle cancer	0.000186	0.00216	CbGpPWpGaD
Dabrafenib—Hypotension—Methotrexate—muscle cancer	0.000185	0.00144	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—muscle cancer	0.000183	0.00143	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—muscle cancer	0.000182	0.00141	CcSEcCtD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000181	0.0021	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000181	0.0014	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR—MDM2—muscle cancer	0.000179	0.00208	CbGpPWpGaD
Dabrafenib—Insomnia—Methotrexate—muscle cancer	0.000179	0.00139	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—muscle cancer	0.000179	0.00139	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—muscle cancer	0.000179	0.00139	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000178	0.00138	CcSEcCtD
Dabrafenib—RAF1—Signaling by NGF—FOXO4—muscle cancer	0.000178	0.00206	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000177	0.00206	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—KIT—muscle cancer	0.000176	0.00204	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000176	0.00204	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000175	0.00203	CbGpPWpGaD
Dabrafenib—Dry mouth—Doxorubicin—muscle cancer	0.000175	0.00136	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—muscle cancer	0.000172	0.00134	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—muscle cancer	0.000172	0.00133	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000171	0.00133	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—muscle cancer	0.000171	0.00133	CcSEcCtD
Dabrafenib—LIMK1—Immune System—FOXO4—muscle cancer	0.000171	0.00198	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000171	0.00198	CbGpPWpGaD
Dabrafenib—Infection—Doxorubicin—muscle cancer	0.00017	0.00133	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—MYOD1—muscle cancer	0.000169	0.00196	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000169	0.00196	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000168	0.00196	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Doxorubicin—muscle cancer	0.000168	0.00131	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—muscle cancer	0.000168	0.00131	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR in disease—MDM2—muscle cancer	0.000167	0.00194	CbGpPWpGaD
Dabrafenib—Skin disorder—Doxorubicin—muscle cancer	0.000167	0.0013	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—muscle cancer	0.000166	0.00129	CcSEcCtD
Dabrafenib—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000166	0.00193	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—KIT—muscle cancer	0.000166	0.00192	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—KIT—muscle cancer	0.000165	0.00191	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIDINS220—muscle cancer	0.000163	0.00189	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Methotrexate—muscle cancer	0.000162	0.00126	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—muscle cancer	0.00016	0.00125	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—KIT—muscle cancer	0.000158	0.00184	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000158	0.00184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KIT—muscle cancer	0.000158	0.00183	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—KIT—muscle cancer	0.000157	0.00182	CbGpPWpGaD
Dabrafenib—Abdominal pain—Methotrexate—muscle cancer	0.000157	0.00122	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—muscle cancer	0.000157	0.00122	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—VEGFA—muscle cancer	0.000156	0.00182	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000156	0.00122	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—KIT—muscle cancer	0.000156	0.00181	CbGpPWpGaD
Dabrafenib—Insomnia—Doxorubicin—muscle cancer	0.000155	0.00121	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—MED12—muscle cancer	0.000154	0.00179	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—FH—muscle cancer	0.000152	0.00177	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000152	0.00176	CbGpPWpGaD
Dabrafenib—Decreased appetite—Doxorubicin—muscle cancer	0.000149	0.00116	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000148	0.00115	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000148	0.00172	CbGpPWpGaD
Dabrafenib—Fatigue—Doxorubicin—muscle cancer	0.000148	0.00115	CcSEcCtD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000148	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KIT—muscle cancer	0.000147	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KIT—muscle cancer	0.000147	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000147	0.0017	CbGpPWpGaD
Dabrafenib—Constipation—Doxorubicin—muscle cancer	0.000147	0.00114	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—muscle cancer	0.000146	0.00113	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000146	0.00169	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KIT—muscle cancer	0.000145	0.00169	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KIT—muscle cancer	0.000145	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000144	0.00167	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000144	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KIT—muscle cancer	0.000144	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD34—muscle cancer	0.000143	0.00166	CbGpPWpGaD
Dabrafenib—Asthenia—Methotrexate—muscle cancer	0.000142	0.00111	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00014	0.00109	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—muscle cancer	0.00014	0.00109	CcSEcCtD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000139	0.00162	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MDM2—muscle cancer	0.000139	0.00161	CbGpPWpGaD
Dabrafenib—Abdominal pain—Doxorubicin—muscle cancer	0.000136	0.00105	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—muscle cancer	0.000136	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—muscle cancer	0.000136	0.00105	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000133	0.00154	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000131	0.00152	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FOXO1—muscle cancer	0.000131	0.00152	CbGpPWpGaD
Dabrafenib—Dizziness—Methotrexate—muscle cancer	0.000131	0.00102	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—MDM2—muscle cancer	0.000131	0.00152	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.00013	0.00151	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00013	0.00151	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MDM2—muscle cancer	0.00013	0.00151	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Doxorubicin—muscle cancer	0.000126	0.000983	CcSEcCtD
Dabrafenib—LIMK1—Immune System—FOXO1—muscle cancer	0.000126	0.00146	CbGpPWpGaD
Dabrafenib—Vomiting—Methotrexate—muscle cancer	0.000126	0.000979	CcSEcCtD
Dabrafenib—Rash—Methotrexate—muscle cancer	0.000125	0.000971	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—muscle cancer	0.000125	0.00097	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—MDM2—muscle cancer	0.000125	0.00145	CbGpPWpGaD
Dabrafenib—Headache—Methotrexate—muscle cancer	0.000124	0.000965	CcSEcCtD
Dabrafenib—RAF1—Signaling by FGFR—MDM2—muscle cancer	0.000124	0.00144	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—VEGFA—muscle cancer	0.000124	0.00144	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—MDM2—muscle cancer	0.000123	0.00143	CbGpPWpGaD
Dabrafenib—Asthenia—Doxorubicin—muscle cancer	0.000123	0.000957	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—MDM2—muscle cancer	0.000123	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—muscle cancer	0.000123	0.00142	CbGpPWpGaD
Dabrafenib—Pruritus—Doxorubicin—muscle cancer	0.000121	0.000944	CcSEcCtD
Dabrafenib—BRAF—Focal Adhesion—VEGFA—muscle cancer	0.00012	0.00139	CbGpPWpGaD
Dabrafenib—Nausea—Methotrexate—muscle cancer	0.000118	0.000915	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—muscle cancer	0.000117	0.000913	CcSEcCtD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.000117	0.00136	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—MDM2—muscle cancer	0.000116	0.00135	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000116	0.00134	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—MDM2—muscle cancer	0.000116	0.00134	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000116	0.00134	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—MDM2—muscle cancer	0.000116	0.00134	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—MDM2—muscle cancer	0.000115	0.00133	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—MDM2—muscle cancer	0.000114	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000114	0.00132	CbGpPWpGaD
Dabrafenib—Dizziness—Doxorubicin—muscle cancer	0.000113	0.000882	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—MDM2—muscle cancer	0.000113	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIDINS220—muscle cancer	0.000113	0.00131	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VEGFA—muscle cancer	0.000112	0.0013	CbGpPWpGaD
Dabrafenib—Vomiting—Doxorubicin—muscle cancer	0.000109	0.000848	CcSEcCtD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000109	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000109	0.00126	CbGpPWpGaD
Dabrafenib—Rash—Doxorubicin—muscle cancer	0.000108	0.000841	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—muscle cancer	0.000108	0.00084	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—muscle cancer	0.000108	0.000836	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000105	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000105	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000102	0.00119	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—FH—muscle cancer	0.000102	0.00119	CbGpPWpGaD
Dabrafenib—Nausea—Doxorubicin—muscle cancer	0.000102	0.000792	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—FOXO4—muscle cancer	0.000101	0.00118	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000101	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KIT—muscle cancer	0.0001	0.00116	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—muscle cancer	0.0001	0.00116	CbGpPWpGaD
Dabrafenib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	9.87e-05	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FOXO4—muscle cancer	9.73e-05	0.00113	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ENO2—muscle cancer	9.66e-05	0.00112	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KIT—muscle cancer	9.6e-05	0.00111	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—FH—muscle cancer	9.48e-05	0.0011	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	9.11e-05	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IGF2—muscle cancer	9.03e-05	0.00105	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HMGA1—muscle cancer	8.78e-05	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD34—muscle cancer	8.68e-05	0.00101	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MED12—muscle cancer	8.61e-05	0.000999	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—FOXO1—muscle cancer	8.47e-05	0.000984	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—muscle cancer	8.39e-05	0.000974	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—muscle cancer	8.29e-05	0.000963	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.26e-05	0.000959	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—MDM2—muscle cancer	8.03e-05	0.000932	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	7.89e-05	0.000916	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FOXO4—muscle cancer	7.88e-05	0.000914	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MDM2—muscle cancer	7.87e-05	0.000914	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO2—muscle cancer	7.85e-05	0.000911	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MDM2—muscle cancer	7.56e-05	0.000878	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTCH1—muscle cancer	7.51e-05	0.000872	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FOXO1—muscle cancer	7.48e-05	0.000869	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.46e-05	0.000866	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	7.35e-05	0.000853	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FOXO1—muscle cancer	7.19e-05	0.000834	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—muscle cancer	6.92e-05	0.000803	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—muscle cancer	6.69e-05	0.000776	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTCH1—muscle cancer	6.41e-05	0.000745	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CNR1—muscle cancer	6.34e-05	0.000736	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.24e-05	0.000724	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.14e-05	0.000713	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HMGA1—muscle cancer	6.08e-05	0.000705	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOXO4—muscle cancer	5.9e-05	0.000685	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FH—muscle cancer	5.88e-05	0.000683	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FOXO1—muscle cancer	5.82e-05	0.000675	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MED12—muscle cancer	5.78e-05	0.000672	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—muscle cancer	5.7e-05	0.000662	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FOXO4—muscle cancer	5.52e-05	0.00064	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—muscle cancer	5.48e-05	0.000636	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FOXO4—muscle cancer	5.45e-05	0.000633	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CNR1—muscle cancer	5.41e-05	0.000629	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—muscle cancer	5.41e-05	0.000628	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MED12—muscle cancer	5.36e-05	0.000622	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—muscle cancer	5.27e-05	0.000612	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.13e-05	0.000595	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FH—muscle cancer	5.12e-05	0.000595	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	4.94e-05	0.000574	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—muscle cancer	4.88e-05	0.000567	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MDM2—muscle cancer	4.49e-05	0.000521	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH1—muscle cancer	4.44e-05	0.000515	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—muscle cancer	4.43e-05	0.000515	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF2—muscle cancer	4.43e-05	0.000514	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOXO1—muscle cancer	4.36e-05	0.000506	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—MDM2—muscle cancer	4.31e-05	0.000501	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.12e-05	0.000479	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FOXO1—muscle cancer	4.07e-05	0.000473	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FOXO1—muscle cancer	4.02e-05	0.000467	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.89e-05	0.000452	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—muscle cancer	3.86e-05	0.000448	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FOXO4—muscle cancer	3.82e-05	0.000443	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—muscle cancer	3.79e-05	0.00044	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CNR1—muscle cancer	3.75e-05	0.000435	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MDM2—muscle cancer	3.49e-05	0.000405	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—muscle cancer	3.37e-05	0.000391	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MED12—muscle cancer	3.32e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—muscle cancer	3.32e-05	0.000386	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FH—muscle cancer	3.16e-05	0.000367	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—muscle cancer	3.1e-05	0.00036	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—muscle cancer	3.07e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—muscle cancer	3.06e-05	0.000356	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—muscle cancer	3.03e-05	0.000352	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.94e-05	0.000342	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MED12—muscle cancer	2.9e-05	0.000336	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—muscle cancer	2.86e-05	0.000332	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FOXO1—muscle cancer	2.82e-05	0.000327	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—muscle cancer	2.73e-05	0.000317	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—muscle cancer	2.64e-05	0.000306	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MDM2—muscle cancer	2.62e-05	0.000304	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—muscle cancer	2.44e-05	0.000284	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—muscle cancer	2.42e-05	0.00028	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.37e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—muscle cancer	2.33e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—muscle cancer	2.15e-05	0.000249	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—muscle cancer	1.86e-05	0.000215	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—muscle cancer	1.84e-05	0.000213	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MED12—muscle cancer	1.78e-05	0.000207	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—muscle cancer	1.7e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—muscle cancer	1.69e-05	0.000196	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—muscle cancer	1.63e-05	0.000189	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—muscle cancer	1.4e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—muscle cancer	1.28e-05	0.000149	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.06e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—muscle cancer	9.7e-06	0.000113	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—muscle cancer	9.2e-06	0.000107	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—muscle cancer	5.67e-06	6.58e-05	CbGpPWpGaD
